Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

Visterra Partners with A*STAR to Develop VIS513, a Monoclonal Antibody for Dengue

May 21, 2015

- Key Development Activities of the Collaboration Will Be Conducted in Singapore -

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

Editas Medicine Presents Data from Multiple Therapeutic Discovery Programs Emerging from its Genome Editing Platform at the ASGCT Annual Conference

May 18, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Editas Medicine, a leading genome editing company, today announced data from several emerging therapeutic discovery programs, as well as data from advancements in its technology platform. Together these data demonstrate the breadth of research underway at Editas Medicine to translate the promise of genome editing technology into new medicines. The data were presented at the 18th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting in New Orleans.

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

May 18, 2015

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to luspatercept for two separate indications; the use of luspatercept for the treatment of patients with transfusion dependent beta-thalassemia and the use of luspatercept for the treatment of patients with non-transfusion dependent beta-thalassemia. Celgene and Acceleron are jointly developing luspatercept.

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

Agios Announces FDA Fast Track Designation Granted to AG-120 for Treatment of Patients with Acute Myelogenous Leukemia with an IDH1 Mutation

May 18, 2015

CAMBRIDGE, Mass., May 18, 2015 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AG-120 for the treatment of patients with acute myelogenous leukemia (AML) who harbor an isocitrate dehydrogenase-1 (IDH1) mutation.

Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases

Denali Therapeutics Launches with Initial Investment to Discover and Develop Treatments for Neurodegenerative Diseases

May 14, 2015

SAN FRANCISCO, May 14, 2015 – Denali Therapeutics Inc. (“Denali”), a new biotechnology company focused on developing effective therapies for neurodegenerative diseases, announced today that it has launched with an initial investment commitment of $217 million. Denali is based on the collaboration of world-class scientists, industry experts and investors.

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

May 13, 2015

Collaboration to pioneer first-of-a-kind gene therapies enabling multiple dosing

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

Sanofi Exercises Option on Second Therapeutic Program with Selecta Biosciences to Develop an Antigen-Specific Immunotherapy Based on Synthetic Vaccine Particle Technology

May 13, 2015

Celiac disease program added to 2012 alliance addressing immune disorders related to food and airborne allergens

Selecta eligible to receive payments totaling up to $300 million as well as up to double digit tiered royalties on product sales of immune tolerance product for each program under the alliance

Moderna #1 on CNBC Disruptor 50 List

Moderna #1 on CNBC Disruptor 50 List

May 12, 2015

CAMBRIDGE, Mass., May 12, 2015 — Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) TherapeuticsTM, today announced it has been named the top Disruptor on the third-annual CNBC Disruptor 50 list. For the second year in a row, CNBC recognizes Moderna as one of the country’s most ambitious and innovative companies changing the economy and overall business landscape.

Moderna Launches Third Venture Company Elpidera for Rare Diseases

Moderna Launches Third Venture Company Elpidera for Rare Diseases

May 12, 2015

Greg Licholai, M.D., hired as president to lead the venture to advance novel messenger RNA therapies

Joule Secures $40 Million for Continued Growth

Joule Secures $40 Million for Continued Growth

May 11, 2015

Bedford, Mass. – May 11, 2015 – Joule, the pioneer of liquid fuels from recycled CO2, today announced the closing of $40 million in private equity and venture debt financing, supporting the company’s growth towards commercialization. The round was led by existing investors, including Flagship Ventures, and brings the company’s total to $200 million raised to date.